Emergent BioSolutions (EBS) Tops Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $7.05 -0.56%
Revenue Growth %: -45.6%
Financial Fact:
Other income (expense), net: -234K
Today's EPS Names:
MGYR, EACO, FMBH, More
Revenue Growth %: -45.6%
Financial Fact:
Other income (expense), net: -234K
Today's EPS Names:
MGYR, EACO, FMBH, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.75, $0.13 better than the analyst estimate of $0.62. Revenue for the quarter came in at $270.7 million versus the consensus estimate of $270.03 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stagwell Inc (STGW) Tops Q3 EPS by 3c ; Offers Guidance
- Magyar Bancorp (MGYR) Tops Q4 EPS by 52c
- Meta Platforms shares rise after Ackman calls stock undervalued
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
